Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

The Retinoblastoma Gene

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Transformation of ALK-translocated lung adenocarcinoma to LCNEC under alectinib treatment - a case report and mini-review.

The oncologist·2026

Same author

Toxicity-over-time analysis of anti-EGFR-based maintenance versus stop&go in left-sided, RAS/BRAF wild-type metastatic colorectal cancer.

Journal of the National Cancer Institute·2026

Same author

Impact of culture dimensionality and matrix composition on morphology, phenotype and drug response in pancreatic cancer models.

Scientific reports·2026

Same author

BRAF<sup>V600E</sup> patient derived colon cancer organoids identify biomarkers of response to EGFR and BRAF inhibition and replicate clinical data.

Journal of experimental & clinical cancer research : CR·2026

Same author

PROTECTOR / FIRE‑10: study protocol for a prospective, randomized, open-label, multicenter phase III trial to investigate the efficacy of preoperative systemic therapy in advanced colon cancer.

BMC cancer·2026

Same author

Diagnosis and treatment of human epidermal growth factor receptor 2-positive metastatic colorectal cancer: a systematic literature review.

Cancer treatment reviews·2026

Search research articles

Related Experiment Video

Updated: Jun 13, 2025

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis

Published on: December 9, 2016

Recurrent Intracranial Ewing Sarcoma.

Soo Ann Yap^1,2,3, Annabel Helga Sophie Alig¹, Alena Annbalou Hasenburg¹

¹Department of Hematology, Oncology and Cancer Immunology, Charité Universitätsmedizin, Berlin, Germany.

Ochsner Journal

|September 16, 2024

Summary

Recurrent Ewing sarcoma presents a significant challenge, with survival rates improving through individualized, multidisciplinary care. This case highlights the importance of tailored treatment strategies for rare, aggressive cancers.

Keywords:

Chemotherapy–adjuvant neoplasm metastasis radiotherapy sarcoma–Ewing soft tissue neoplasms

More Related Videos

Surgical Treatment of an Endolymphatic Sac Tumor

Surgical Treatment of an Endolymphatic Sac Tumor

Published on: May 26, 2023

Role of Diffusion MRI Tractography in Endoscopic Endonasal Skull Base Surgery

Role of Diffusion MRI Tractography in Endoscopic Endonasal Skull Base Surgery

Published on: July 5, 2021

Related Experiment Videos

Last Updated: Jun 13, 2025

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis

Published on: December 9, 2016

Surgical Treatment of an Endolymphatic Sac Tumor

Surgical Treatment of an Endolymphatic Sac Tumor

Published on: May 26, 2023

Role of Diffusion MRI Tractography in Endoscopic Endonasal Skull Base Surgery

Role of Diffusion MRI Tractography in Endoscopic Endonasal Skull Base Surgery

Published on: July 5, 2021

Area of Science:

Oncology
Pediatric Oncology
Skeletal Tumors

Background:

Ewing sarcoma is a rare bone cancer with improved outcomes for localized disease.
Disseminated or recurrent Ewing sarcoma has a poor prognosis (<30% 5-year survival).

Observation:

A 17-year-old female with left temple Ewing sarcoma initially achieved partial remission with chemotherapy but refused further treatment.
The patient returned with disease progression after 7 months, necessitating re-treatment.
Chemotherapy per EURO EWING 2012 trial, debulking surgery, and radiation were administered.

Findings:

Partial remission was achieved following a multimodal approach for recurrent Ewing sarcoma.
Individualized treatment based on patient response and tumor board decisions is crucial.

Implications:

Optimal treatment protocols for recurrent Ewing sarcoma are not well-established.
Multidisciplinary collaboration is vital for improving care and outcomes in rare tumors like Ewing sarcoma.